MetaVia Inc. (MTVA)
Automate Your Wheel Strategy on MTVA
With Tiblio's Option Bot, you can configure your own wheel strategy including MTVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MTVA
- Rev/Share 0.0
- Book/Share 0.9183
- PB 0.7242
- Debt/Equity 0.0171
- CurrentRatio 1.9432
- ROIC -3.5712
- MktCap 13026220.0
- FreeCF/Share -2.8619
- PFCF -0.527
- PE -0.2082
- Debt/Assets 0.0084
- DivYield 0
- ROE -2.2117
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MTVA | H.C. Wainwright | -- | Buy | -- | $12 | Dec. 30, 2024 |
News
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , May 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA) ("MetaVia"), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a private placement that MetaVia estimates will result in gross proceeds of approximately $10.0 million, before deducting the placement agent's fees and other offering expenses payable by the company.
Read More
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
DA-1241 Significantly Decreased Plasma ALT levels, with a Mean Reduction of 22.8 U/L After 16 Week-Treatment Controlled Attenuation Parameter (CAP) Score Improved by 23.0 dB/m, Indicating Reduced Liver Fat Content Improvement in Systemic Inflammatory and Fibrosis Biomarkers Supports Beneficial Effects on Liver Health CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that data from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects.
Read More
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks Additional Cohorts Being Added to Determine Maximum Tolerated Dose CAMBRIDGE, Mass. , April 22, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic …
Read More
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025 Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect $16.0 Million in Cash at End of Fourth Quarter E xpected to Fund the Company Into the Third Quarter of 2025 CAMBRIDGE, Mass. , March 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, …
Read More
About MetaVia Inc. (MTVA)
- IPO Date 2016-08-05
- Website https://www.metaviatx.com
- Industry Biotechnology
- CEO Heon Kim Hyung
- Employees 9